2026-10-14T04:55:31Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34034704 2026-09-30T17:27:00Z category_4 category_12 category_13 category_14 category_15 category_873 category_734 category_64 portal_5 item_type_3 month_year_09_2026

<p>Antibodies used for <i>in vitro</i> investigations.</p> Noelle Callizot (5660677) Georgia Culley (15148575) Grace Flower (25145065) Laura Rouvière (16400955) Véronique De Conto (25145068) Alexandre Wojcinski (6340172) Catherine Botto (25145071) Cecilia Estrella (1618609) Alexandre Henriques (359791) Philippe Verwaerde (1618624) Biochemistry Cell Biology Genetics Molecular Biology Neuroscience Chemical Sciences not elsewhere classified Biological Sciences not elsewhere classified Cancer promising therapeutic approach lewy bodies ). several lysosomal enzymes restoring lysosomal homeostasis lysosomal availability depend like models (< parkinson &# 8217 maintaining lysosomal function div >< p neuroprotective effects involve several parkinson ’ lysosomal function neuroprotective effects lysosomal system lysosomal dysfunction parkinson ’ neuroprotective action disease models vivo </ vitro </ ultimately supporting prone proteins pathohistological hallmarks mitochondrial injury genetic connections endoplasmic reticulum dopaminergic neurons direct link clinical development <div><p>The pathohistological hallmarks of Parkinson’s disease are aggregated alpha-synuclein and other aggregation-prone proteins (Lewy bodies). Recent studies show mechanistic as well as genetic connections between lysosomal dysfunction and Parkinson’s disease pathology. A direct link between lysosomal function and Parkinson’s disease might be the degradation of alpha-synuclein within the lysosomal system. Progranulin is necessary for maintaining lysosomal function, facilitating the activity of several lysosomal enzymes. Progranulin’s exit from the endoplasmic reticulum and its lysosomal availability depend on an interaction with Prosaposin. AZP2006 (INN: Ezeprogind) is a small lysosomotropic neuroprotective molecule currently in clinical development in Progressive Supranuclear Palsy patients. Its neuroprotective effects involve the Progranulin/Prosaposin complex. In this study, we investigated the neuroprotective effects of AZP2006 in several Parkinson’s-like models (<i>vitro</i> and <i>vivo</i>). We showed that AZP2006 was able to counteract a mitochondrial injury as well as the toxicity of alpha-synuclein preformed fibril spreading. We proved that Progranulin was involved in AZP2006’s neuroprotective action, restoring lysosomal homeostasis and ultimately supporting the health of dopaminergic neurons. In light of this evidence, strategies with the aim of improving Progranulin and Prosaposin levels and activity offer a promising therapeutic approach in the context of proteinopathies such as Parkinson’s disease.</p></div> 2026-09-30T17:26:42Z Dataset Dataset 10.1371/journal.pone.0359269.t001 https://figshare.com/articles/dataset/_p_Antibodies_used_for_i_in_vitro_i_investigations_p_/34034704 CC BY 4.0